查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1983731

體外肺模型市場：2026-2032年全球市場預測（按產品類型、模型類型、細胞來源、技術、應用和最終用戶分類）

In Vitro Lung Model Market by Product Type, Model Type, Cell Source, Technology, Application, End Users - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，體外肺模型市場價值將達到 8.0258 億美元，到 2026 年將成長至 9.3848 億美元，到 2032 年將達到 25.0275 億美元，年複合成長率為 17.64%。

主要市場統計數據
基準年 2025 8.0258億美元
預計年份：2026年 9.3848億美元
預測年份 2032 25.0275億美元
複合年成長率 (%) 17.64%

在科學和監管趨勢的共同推動下，體外肺模型正成為重塑轉化和商業策略的核心臨床前資產。

呼吸系統研究和臨床前試驗領域正經歷著一場重大變革，其驅動力包括科學進步、監管機構對高度相關的人體模型的重視，以及日益成長的減少動物試驗依賴的需求。體外肺模型，包括2D培養、3D類器官、晶片器官平台和精密切片組織，結合細胞獲取、微加工技術和生物工程方面的創新，為疾病建模和藥物測試提供了高度預測性和可擴展的替代方案。這種融合正在重塑研究人員檢驗作用機制、篩檢候選藥物和評估呼吸毒性的方式。

透過技術整合和跨學科合作，客製化的體外肺實驗正在轉變為擴充性和檢驗的平台，為監管和商業化鋪平道路。

體外肺模型的研究格局正從孤立的概念驗證實驗轉向能夠為藥物發現、開發和監管合作等各個環節的決策提供資訊的綜合平台。微流體、支架工程和幹細胞分化等技術的成熟，使得建構能夠更真實地再現肺泡和支氣管微環境、細胞異質性和動態力學作用的模型成為可能。因此，研究人員能夠以更高的生理保真度闡明疾病機制，並進行與臨床應用更相關的試驗，涵蓋從小分子化合物到生物製藥和細胞療法等各個方面。

供應鏈關稅的變化可能需要重組籌資策略，並促進體外肺模型材料的本地化生產。

關稅政策的變化會影響從事體外肺模型技術和試劑設計、製造、分銷或採購的機構的商業決策。影響進口實驗室設備、微流體組件或專用生物試劑的貿易措施可能會改變採購計畫和單價，尤其對於依賴跨境供應鏈的研究機構和公司而言更是如此。如果關稅增加關鍵材料的採購成本，機構可能需要考慮短期調整措施，例如尋找替代供應商、提前採購或本地生產，以維持實驗的連續性。

多層細分框架揭示了模型類型、應用、電池來源、技術、產品類型和最終用戶需求如何相互交織，並塑造採用趨勢和策略重點。

精細化的市場細分框架對於理解整個體外肺模型市場的客戶需求、技術適用性和轉換效用至關重要。就模型類型而言，該市場涵蓋2D細胞培養、3D類器官、晶片肺系統和精密切割的肺切片。在2D細胞培養中，細胞株培養和原代細胞培養之間存在進一步的區分，這反映了通量、生理有效性和獲取複雜性方面的差異。3D類器官類別進一步細分為肺泡類器官和支氣管類器官，分別滿足特定的疾病建模和藥物反應分析需求。基於應用的細分明確了疾病建模、藥物發現與開發、個人化醫療和毒性測試等最終用途，並將特定的實驗目標與最佳模型分類連結起來。細胞來源分析區分了動物源性細胞、細胞株和人源性細胞。人源細胞可細分為初代細胞和幹細胞衍生細胞，此區分對轉化應用和法規核准具有重要意義。基於技術的細分主要包括微流體、支架培養和無支架培養。微流體系統可進一步分為連續流系統和液滴系統；支架培養可分為天然支架和合成支架；無支架培養則分為生物反應器和懸滴法。每種選擇都需在複雜性、擴充性和生理模擬性之間權衡取捨。產品類型主要分為儀器和試劑盒/試劑，終端用戶涵蓋學術和研究機構、受託研究機構(CRO)、製藥和生物技術公司以及監管機構。將這些細分與客戶優先事項相匹配，可以揭示生理保真度、通量、成本效益和法規遵從性方面的需求的交集和差異，從而幫助平台提供者識別策略機遇，最佳化針對不同用戶群的價值提案。

區域生態系統和政策框架正在推動美洲、歐洲、中東、非洲和亞太地區體外肺模型部署模式的差異化。

區域趨勢正在影響體外肺模型開發和應用所需的人才、資金、法規結構和製造生態系統的獲取。美洲地區集中了眾多轉化研究中心、生物技術叢集和合約研究機構，這些機構有助於新平台的快速應用，並促進學術創新者和商業開發商之間的夥伴關係。該地區的監管環境和支付方趨勢也在推動人源模型的需求，這些模型可以加快研發進度並降低後期失敗的風險。

市場領先的公司正在建立整合平台生態系統，將工程模型、標準化通訊協定和數位分析相結合，以降低採用門檻並提高轉換研究的可信度。

體外肺模型領域的競爭格局由專業技術供應商、儀器製造商、試劑開發商和服務型合約研究組織 (CRO) 組成。主要企業正投資於平台能力建設，力求將卓越的工程技術和生物學保真度相結合，許多企業也在尋求策略夥伴關係，以擴大轉化檢驗和市場覆蓋範圍。將模組化硬體與靈活的試劑套件結合的企業往往更受廣大終端用戶的青睞，因為它們降低了實驗的技術門檻，同時又能滿足高級應用的客製化需求。

為了加快部署速度並降低營運風險，應優先考慮交叉檢驗、模組化產品設計、策略夥伴關係、在地採購數位資料整合。

產業領導企業應優先考慮加快檢驗、擴大應用範圍，並使平台開發與監管和臨床證據需求保持一致。首先，應投資進行交叉驗證研究，將體外模型輸出與特徵明確的臨床終點和已建立的體內基準進行比較，以增強轉化相關性的論點。其次，應開發模組化產品套件，提供清晰的升級路徑，特別是將支援高通量篩檢的基礎配置與可增加生理複雜性以用於後期試驗的高階模組相結合。第三，應擴大與合約研究機構和學術機構的合作，以建立共用的檢驗資料集，並加強對最終用戶的技術支援。

我們透明且多方面的調查方法，結合專家訪談、同儕審查的證據、監管文件和情境分析，為令人信服的見解和建議提供了支持。

本報告整合了結構化的質性訪談、二手文獻和技術檢驗框架，以產生平衡且可重複的分析。主要輸入包括與學術機構、受託研究機構和商業機構的科學家、研發負責人和採購專家進行的深入討論，從而深入了解買方需求、技術挑戰和檢驗預期。二級資訊來源包括同行評審文章、監管指導文件、專利趨勢和企業披露訊息，揭示了技術藍圖和轉換證據。

要實現轉化潛力需要嚴格的檢驗、支持性的生態系統和策略性的商業化，才能將體外肺模型的進展轉化為永續的臨床和商業性價值。

體外肺模型正從單純的研究新奇事物發展成為對藥物發現、安全性評估和轉化決策有重大影響的基礎工具。微流體、人工支架和幹細胞生物學等技術的融合，使得建構生理保真度更高的模型成為可能；同時，數據分析技術的進步也使得對細胞反應的解讀更加深入。這些進步，加上不斷變化的監管要求和策略性供應鏈重組，意味著能夠將檢驗的體外數據整合到其研發流程中的企業，將在降低臨床專案風險和加快產品上市速度方面獲得競爭優勢。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：體外肺模型市場：依產品類型分類

  • 裝置
  • 試劑盒和試劑

第9章：體外肺模型市場（依模型類型分類）

  • 2D細胞培養
    • 細胞株培養
    • 原代細胞培養
  • 3D類器官
    • 肺泡類器官
    • 支氣管類器官
  • Lung-On-A-Chip
  • 精準肺切片

第10章：體外肺模型市場（依細胞來源分類）

  • 動物源性細胞
  • 細胞株
  • 人類來源細胞
    • 原代細胞
    • 幹細胞衍生細胞

第11章：體外肺模型市場：依技術分類

  • 微流體技術
    • 連續流系統
    • 基於液滴的系統
  • 利用支架進行培養
    • 天然鷹架
    • 複合支架
  • 無需支架的文化
    • 生物反應器
    • 懸垂

第12章：體外肺模型市場：依應用領域分類

  • 疾病建模
  • 藥物發現與開發
  • 個人化醫療
  • 毒性測試

第13章：體外肺模型市場：依最終用戶分類

  • 學術和研究機構
  • CRO
  • 製藥和生物技術公司
  • 監管機構

第14章：體外肺模型市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：體外肺模型市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：體外肺模型市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國體外肺部模型市場

第18章：中國體外肺模型市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AlveoliX AG
  • Brainlab AG
  • Cn Bio Innovations Limited
  • Emulate, Inc.
  • Epithelix Sarl
  • Hologic, Inc.
  • Horizon Discovery Group plc
  • Insphero AG
  • Lonza Group AG
  • Mattek Corporation by Bico Group
  • McKesson Corporation
  • Merck KGaA
  • MICA Information Systems, Inc.
  • Mimetas BV
  • PromoCell GmbH
  • STEMCELL Technologies Inc.
  • Thermo Fisher Scientific Inc
  • Tissuse GmbH
  • Varian Medical Systems, Inc
Product Code: MRR-F6513A06BD96

The In Vitro Lung Model Market was valued at USD 802.58 million in 2025 and is projected to grow to USD 938.48 million in 2026, with a CAGR of 17.64%, reaching USD 2,502.75 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 802.58 million
Estimated Year [2026] USD 938.48 million
Forecast Year [2032] USD 2,502.75 million
CAGR (%) 17.64%

A converging scientific and regulatory momentum is elevating in vitro lung models into central preclinical assets that reshape translational and commercial strategies

The landscape of respiratory research and preclinical testing is experiencing a profound transformation driven by scientific advances, regulatory emphasis on human-relevant models, and a growing imperative to reduce reliance on animal studies. In vitro lung models-encompassing two-dimensional cultures, three-dimensional organoids, organ-on-chip platforms, and precision-cut tissue slices-are converging with innovations in cellular sourcing, microfabrication, and bioengineering to offer increasingly predictive and scalable alternatives for disease modeling and drug testing. This convergence is reshaping how researchers validate mechanisms of action, screen therapeutic candidates, and assess respiratory toxicology.

These advances come at a moment when pharmaceutical and biotechnology developers are accelerating respiratory pipelines in response to persistent unmet needs across chronic and acute pulmonary conditions. Simultaneously, regulatory agencies and ethical oversight bodies are signaling stronger expectations for human-relevant data to support safety and efficacy claims. Together, these drivers are elevating in vitro lung models from specialized academic tools to core components of translational research strategies. The introduction outlines how the interplay of technological, regulatory, and commercial forces is redefining expectations for preclinical confidence and operational scalability, and sets the stage for the deeper thematic analysis that follows.

Technological integration and cross-sector collaboration are converting bespoke in vitro lung experiments into scalable, validated platforms that inform regulatory and commercial pathways

The in vitro lung model landscape is shifting from isolated proof-of-concept experiments toward integrated platforms that can feed decision-making across discovery, development, and regulatory interaction. Technological maturation in microfluidics, scaffold engineering, and stem cell differentiation is enabling models that better recapitulate alveolar and bronchial microenvironments, cellular heterogeneity, and dynamic mechanical forces. As a result, researchers can explore disease mechanisms at greater physiological fidelity and test modalities ranging from small molecules to biologics and cell therapies with improved translational relevance.

Parallel to technological progress, partnerships between academia, industry, and contract research organizations are accelerating model standardization, reproducibility studies, and cross-validation against clinical endpoints. These collaborations are reducing barriers to adoption by establishing shared protocols and quality benchmarks. In addition, digital augmentation-integrating high-content imaging, multi-omics readouts, and AI-driven analytics-is amplifying the interpretative power of in vitro assays and enabling more granular phenotyping of cellular responses. Collectively, these shifts are transforming in vitro lung models from bespoke experimental tools into scalable, validated platforms that can be incorporated into regulatory strategies and commercial development pathways.

Tariff-driven supply chain shifts can reshape procurement strategies and incentivize regional manufacturing localization for in vitro lung model inputs

Tariff policy changes can influence the operational calculus for organizations that design, manufacture, distribute, or source in vitro lung model technologies and reagents. Trade measures that affect imported laboratory instruments, microfluidic components, or specialized biological reagents can alter procurement timelines and unit economics, particularly for research groups and companies reliant on cross-border supply chains. When tariffs increase the landed cost of critical inputs, organizations must evaluate near-term adjustments such as alternative suppliers, forward buying, or localized manufacturing to preserve experimental continuity.

Beyond direct cost impacts, tariff-induced supply chain shifts can accelerate strategic localization of production and distribution networks. Firms may seek to deepen regional supplier relationships or invest in domestic manufacturing capabilities to reduce exposure to tariff volatility. In parallel, contract research organizations and research institutions may broaden their vendor base to include suppliers from tariff-insulated markets, and prioritize inventory management strategies that buffer against abrupt cost changes. Over time, these adaptations can influence where R&D centers and specialized manufacturing clusters concentrate, shaping regional competitive dynamics and access to advanced in vitro lung model capabilities.

A layered segmentation framework reveals how model type, application, cell source, technology, product type, and end-user needs converge to shape adoption and strategic priorities

A nuanced segmentation framework is essential for understanding customer needs, technology fit, and translational utility across the in vitro lung model landscape. When considering model type, the market spans 2D cell cultures, 3D organoids, lung-on-a-chip systems, and precision-cut lung slices. Within 2D cell cultures, a further distinction exists between cell line cultures and primary cell cultures, reflecting differences in throughput, physiological relevance, and sourcing complexity. The 3D organoid category separates into alveolar organoids and bronchial organoids, each serving discrete disease modeling and drug-response interrogation needs. Application-driven distinctions clarify end use across disease modeling, drug discovery and development, personalized medicine, and toxicity testing, linking specific experimental objectives to the most appropriate model class. Cell source analysis differentiates animal-derived cells, cell lines, and human-derived cells; human-derived cells are subdivided into primary cells and stem cell-derived cells, a split with strong implications for translational relevance and regulatory acceptability. Technology-based segmentation highlights microfluidics, scaffold-based cultures, and scaffold-free cultures; microfluidic systems are further categorized into continuous flow systems and droplet-based systems, scaffold-based cultures divide into natural and synthetic scaffold approaches, and scaffold-free cultures separate into bioreactor and hanging drop modalities, each choice signaling trade-offs between complexity, scalability, and physiological mimicry. Product type focuses attention on instruments versus kits and reagents, and end users span academic and research institutes, contract research organizations, pharmaceutical and biotechnology companies, and regulatory agencies. Mapping these segments against customer priorities reveals where demand for physiological fidelity, throughput, cost-efficiency, and regulatory alignment converge or diverge, and it helps identify strategic opportunities for platform providers to tailor value propositions to distinct user cohorts.

Regional ecosystems and policy frameworks are driving differentiated adoption patterns for in vitro lung models across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics influence access to talent, capital, regulatory frameworks, and manufacturing ecosystems that underpin the development and deployment of in vitro lung models. In the Americas, there is a concentration of translational research centers, biotech clusters, and contract research organizations that support rapid adoption of novel platforms and facilitate partnerships between academic innovators and commercial developers. The regulatory environment and payer landscapes in this region also drive demand for human-relevant models that can accelerate development timelines and de-risk late-stage failures.

Across Europe, the Middle East & Africa, the interplay of stringent regulatory expectations, ethical frameworks, and strong academic-industrial linkages promotes rigorous model validation and harmonized standards. Investment in public-private collaborations and translational research hubs supports cross-border technology diffusion, while national strategies in key countries prioritize advanced bioengineering capabilities. In the Asia-Pacific region, rapid capacity expansion, substantial manufacturing capabilities, and a growing base of clinical research infrastructure position the area as a critical producer and consumer of in vitro lung model technologies. Local market growth is also stimulated by government-backed innovation programs and an expanding biotechnology talent pool, creating fertile conditions for both localized production and large-scale adoption.

Market leaders are building integrated platform ecosystems that combine engineered models, standardized protocols, and digital analytics to reduce adoption friction and enhance translational credibility

Competitive dynamics in the in vitro lung model domain reflect a mix of specialized technology providers, instrument manufacturers, reagent developers, and service-oriented contract research organizations. Leading companies are investing in platform capabilities that blend engineering excellence with biological fidelity, and many are pursuing strategic partnerships to expand translational validation and market reach. Firms that combine modular hardware with flexible reagent suites tend to appeal to a broader set of end users because they lower technical barriers to experimentation while enabling customization for advanced applications.

An observable trend among market leaders is the pursuit of ecosystem plays that integrate model platforms with digital analytics and standardized protocols. These strategies reduce friction for adoption by addressing reproducibility concerns and by simplifying data integration across discovery and preclinical workflows. Additionally, companies that actively engage with regulatory bodies and standard-setting consortia gain an advantage by shaping validation paradigms and clarifying evidentiary expectations for product submissions. For newer entrants, differentiation often stems from niche capabilities-such as specialized organoid lines, unique scaffold chemistries, or proprietary microfluidic architectures-that address unmet needs in specific disease areas or testing regimes. Service providers that combine technical expertise with scalable operations remain key partners for organizations seeking to outsource complex assays or to accelerate time to result.

Prioritize cross-validation, modular product design, strategic partnerships, localized sourcing, and digital data integration to accelerate adoption and mitigate operational risks

Industry leaders should prioritize actions that accelerate validation, broaden accessibility, and align platform development with regulatory and clinical evidence needs. First, invest in cross-validation studies that compare in vitro model outputs with well-characterized clinical endpoints and established in vivo benchmarks to strengthen claims of translational relevance. Second, develop modular product suites that offer clear upgrade paths: basic configurations that support high-throughput screening alongside advanced modules that deliver enhanced physiological complexity for late-stage testing. Third, expand partnerships with contract research organizations and academic centers to create shared validation datasets and to scale technical support for end users.

Concurrently, companies should localize supply chain elements where feasible to mitigate tariff risk and to shorten lead times for critical components. Building customer education programs focused on best practices, data interpretation, and regulatory expectations will reduce barriers to adoption and foster market trust. Finally, invest in digital analytics and standardized data formats that enable customers to integrate in vitro outputs with multi-omics and clinical datasets, thereby amplifying the business case for model adoption through clearer pathways to decision-making and downstream commercialization.

A transparent, triangulated methodology combining expert interviews, peer-reviewed evidence, regulatory documents, and scenario analysis to support defensible insights and recommendations

This report synthesizes qualitative interviews, secondary literature, and a structured framework of technical validation to generate a balanced and reproducible analysis. Primary inputs included in-depth discussions with scientists, R&D leaders, and procurement specialists across academic, contract research, and commercial settings to capture buyer requirements, technical pain points, and validation expectations. Secondary sources comprised peer-reviewed publications, regulatory guidance documents, patent landscapes, and company disclosures that illuminate technology roadmaps and translational evidence.

Analytical methods combined comparative technology assessment with scenario-based supply chain analysis to evaluate how procurement and policy variables, including tariffs and regional manufacturing capacity, could influence adoption and strategic positioning. Segment mapping followed an attribute-driven approach that aligns model types, applications, cell sources, and technologies with user priorities and evidence requirements. Throughout the research process, emphasis was placed on triangulation and transparency: assertions are corroborated across multiple data inputs, methodological assumptions are documented, and limitations are acknowledged where evidence remains emergent. This approach ensures that conclusions and recommendations rest on a defensible blend of technical insight, stakeholder perspectives, and observable market behaviors.

Translational promise requires rigorous validation, supportive ecosystems, and strategic commercialization to convert in vitro lung model advances into sustained clinical and commercial value

In vitro lung models are transitioning from research curiosities to foundational tools that can materially influence discovery, safety assessment, and translational decision-making. Technological convergence across microfluidics, engineered scaffolds, and stem cell biology is enabling models with greater physiological fidelity, while improvements in data analytics are unlocking richer interpretations of cellular responses. These advances, coupled with evolving regulatory expectations and strategic supply chain realignments, mean that organizations able to integrate validated in vitro data into development workflows will gain a competitive advantage in de-risking clinical programs and accelerating go-to-market timelines.

Adoption will not be uniform; instead, it will reflect the nuances captured in segmentation and regional dynamics. Companies that invest in validation, standardization, and customer support will increase the speed and breadth of uptake. Equally important, strategic attention to procurement resilience and partnership ecosystems will mitigate external shocks and create scaleable pathways for broader implementation. The conclusion underscores a pragmatic imperative: to translate technological promise into organizational capability, stakeholders must pair scientific innovation with rigorous validation, thoughtful commercial packaging, and proactive engagement with regulatory and standards-setting communities.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. In Vitro Lung Model Market, by Product Type

  • 8.1. Instruments
  • 8.2. Kits & Reagents

9. In Vitro Lung Model Market, by Model Type

  • 9.1. 2D Cell Cultures
    • 9.1.1. Cell Line Cultures
    • 9.1.2. Primary Cell Cultures
  • 9.2. 3D Organoids
    • 9.2.1. Alveolar Organoids
    • 9.2.2. Bronchial Organoids
  • 9.3. Lung-On-A-Chip
  • 9.4. Precision-Cut Lung Slices

10. In Vitro Lung Model Market, by Cell Source

  • 10.1. Animal-Derived Cells
  • 10.2. Cell Lines
  • 10.3. Human-Derived Cells
    • 10.3.1. Primary Cells
    • 10.3.2. Stem Cell-Derived Cells

11. In Vitro Lung Model Market, by Technology

  • 11.1. Microfluidics
    • 11.1.1. Continuous Flow Systems
    • 11.1.2. Droplet-Based Systems
  • 11.2. Scaffold-Based Cultures
    • 11.2.1. Natural Scaffolds
    • 11.2.2. Synthetic Scaffolds
  • 11.3. Scaffold-Free Cultures
    • 11.3.1. Bioreactors
    • 11.3.2. Hanging Drop

12. In Vitro Lung Model Market, by Application

  • 12.1. Disease Modeling
  • 12.2. Drug Discovery & Development
  • 12.3. Personalized Medicine
  • 12.4. Toxicity Testing

13. In Vitro Lung Model Market, by End Users

  • 13.1. Academic & Research Institutes
  • 13.2. CROs
  • 13.3. Pharmaceutical & Biotechnology Companies
  • 13.4. Regulatory Agencies

14. In Vitro Lung Model Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. In Vitro Lung Model Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. In Vitro Lung Model Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States In Vitro Lung Model Market

18. China In Vitro Lung Model Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AlveoliX AG
  • 19.6. Brainlab AG
  • 19.7. Cn Bio Innovations Limited
  • 19.8. Emulate, Inc.
  • 19.9. Epithelix Sarl
  • 19.10. Hologic, Inc.
  • 19.11. Horizon Discovery Group plc
  • 19.12. Insphero AG
  • 19.13. Lonza Group AG
  • 19.14. Mattek Corporation by Bico Group
  • 19.15. McKesson Corporation
  • 19.16. Merck KGaA
  • 19.17. MICA Information Systems, Inc.
  • 19.18. Mimetas B.V.
  • 19.19. PromoCell GmbH
  • 19.20. STEMCELL Technologies Inc.
  • 19.21. Thermo Fisher Scientific Inc
  • 19.22. Tissuse GmbH
  • 19.23. Varian Medical Systems, Inc

LIST OF FIGURES

  • FIGURE 1. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IN VITRO LUNG MODEL MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL IN VITRO LUNG MODEL MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES IN VITRO LUNG MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA IN VITRO LUNG MODEL MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY KITS & REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY KITS & REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY KITS & REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CELL LINE CULTURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CELL LINE CULTURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CELL LINE CULTURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRIMARY CELL CULTURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRIMARY CELL CULTURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRIMARY CELL CULTURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY ALVEOLAR ORGANOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY ALVEOLAR ORGANOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY ALVEOLAR ORGANOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY BRONCHIAL ORGANOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY BRONCHIAL ORGANOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY BRONCHIAL ORGANOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY LUNG-ON-A-CHIP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY LUNG-ON-A-CHIP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY LUNG-ON-A-CHIP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRECISION-CUT LUNG SLICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRECISION-CUT LUNG SLICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRECISION-CUT LUNG SLICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY ANIMAL-DERIVED CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY ANIMAL-DERIVED CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY ANIMAL-DERIVED CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CELL LINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CELL LINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CELL LINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRIMARY CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRIMARY CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRIMARY CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY STEM CELL-DERIVED CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY STEM CELL-DERIVED CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY STEM CELL-DERIVED CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CONTINUOUS FLOW SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CONTINUOUS FLOW SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CONTINUOUS FLOW SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY DROPLET-BASED SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY DROPLET-BASED SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY DROPLET-BASED SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY NATURAL SCAFFOLDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY NATURAL SCAFFOLDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY NATURAL SCAFFOLDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SYNTHETIC SCAFFOLDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SYNTHETIC SCAFFOLDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SYNTHETIC SCAFFOLDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY BIOREACTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY BIOREACTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY BIOREACTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY HANGING DROP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY HANGING DROP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY HANGING DROP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY DISEASE MODELING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY DISEASE MODELING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY DISEASE MODELING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PERSONALIZED MEDICINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PERSONALIZED MEDICINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY TOXICITY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY TOXICITY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY TOXICITY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CROS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CROS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CROS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY REGULATORY AGENCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY REGULATORY AGENCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY REGULATORY AGENCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 229. GCC IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 230. GCC IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. GCC IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. GCC IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2018-2032 (USD MILLION)
  • TABLE 233. GCC IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2018-2032 (USD MILLION)
  • TABLE 234. GCC IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 235. GCC IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2018-2032 (USD MILLION)
  • TABLE 236. GCC IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 237. GCC IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, 2018-2032 (USD MILLION)
  • TABLE 238. GCC IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, 2018-2032 (USD MILLION)
  • TABLE 239. GCC IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, 2018-2032 (USD MILLION)
  • TABLE 240. GCC IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 241. GCC IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 263. BRICS IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 268. G7 IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 269. G7 IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. G7 IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. G7 IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2018-2032 (USD MILLION)
  • TABLE 272. G7 IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2018-2032 (USD MILLION)
  • TABLE 273. G7 IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 274. G7 IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2018-2032 (USD MILLION)
  • TABLE 275. G7 IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 276. G7 IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, 2018-2032 (USD MILLION)
  • TABLE 277. G7 IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, 2018-2032 (USD MILLION)
  • TABLE 278. G7 IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, 2018-2032 (USD MILLION)
  • TABLE 279. G7 IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 280. G7 IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 281. NATO IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 282. NATO IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. NATO IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. NATO IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2018-2032 (USD MILLION)
  • TABLE 285. NATO IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2018-2032 (USD MILLION)
  • TABLE 286. NATO IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 287. NATO IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2018-2032 (USD MILLION)
  • TABLE 288. NATO IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 289. NATO IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, 2018-2032 (USD MILLION)
  • TABLE 290. NATO IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, 2018-2032 (USD MILLION)
  • TABLE 291. NATO IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, 2018-2032 (USD MILLION)
  • TABLE 292. NATO IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 293. NATO IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 294. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED STATES IN VITRO LUNG MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED STATES IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED STATES IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED STATES IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED STATES IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2018-2032 (USD MILLION)
  • TABLE 300. UNITED STATES IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED STATES IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED STATES IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED STATES IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED STATES IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED STATES IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, 2018-2032 (USD MILLION)
  • TABLE 306. UNITED STATES IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 307. UNITED STATES IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 308. CHINA IN VITRO LUNG MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 309. CHINA IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 310. CHINA IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 311. CHINA IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2018-2032 (USD MILLION)
  • TABLE 312. CHINA IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2018-2032 (USD MILLION)
  • TABLE 313. CHINA IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 314. CHINA IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2018-2032 (USD MILLION)
  • TABLE 315. CHINA IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 316. CHINA IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, 2018-2032 (USD MILLION)
  • TABLE 317. CHINA IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, 2018-2032 (USD MILLION)
  • TABLE 318. CHINA IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, 2018-2032 (USD MILLION)
  • TABLE 319. CHINA IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 320. CHINA IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)